Active Stock’s Momentum: Cheesecake Factory Inc (NASDAQ:CAKE), Select Medical Holdings Corporation (NYSE:SEM), United Therapeutics Corporation (NASDAQ:UTHR)

On Wednesday, Shares of Cheesecake Factory Inc (NASDAQ:CAKE), added 5.20% and closed at $55.80 in the last trading session. The last trading range of the stock ranges between $52.88 and $56.40. The Cheesecake Factory®, known for its extensive menu, generous portions and legendary desserts, recently declared the opening of its newest restaurant in Valencia, Calif.

With more than 250 menu selections counting nearly 50 lower calorie SkinnyLicious® dishes and a new “Super” Foods section – handmade, in-house with fresh ingredients – and more than 50 signature cheesecakes and desserts, The Cheesecake Factory’s opening provides exciting new choices for shoppers and area residents.

Featuring imported limestone floors and custom wood columns, hand painted murals and modern lighting, the new restaurant includes the distinctive and contemporary décor that is as creative and imaginative as The Cheesecake Factory’s extensive menu.

Select Medical Holdings Corporation (NYSE:SEM), jumped 0.87% and closed at $11.55 in the last trading session. The last trading range of the stock ranges between $10.40 and $11.55. The company’s Market capitalization is $1.52 Billion with the total Outstanding Shares of 132.33 million. Select Medical Holdings Corporation (“Select Medical”) (SEM) today announced results for its third quarter ended September 30, 2016.

For the third quarter ended September 30, 2016, net operating revenues increased 3.2% to $1,053.8 million, compared to $1,021.1 million for the same quarter, prior year.  Income from operations increased 16.5% to $56.2 million for the third quarter ended September 30, 2016, compared to $48.2 million for the same quarter, prior year.  Net income was $4.0 million for the third quarter ended September 30, 2016, which includes a pre-tax non-operating loss of $1.0 million and a pre-tax loss on early retirement of debt of $10.9 million. Net income was $32.8 million for the third quarter ended September 30, 2015, which includes a pre-tax non-operating gain of $29.6 million. Earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Concentra acquisition costs, Physiotherapy acquisition costs, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries (“Adjusted EBITDA”) for the third quarter ended September 30, 2016 increased 16.1% to $98.1 million, compared to $84.5 million for the same quarter, prior year.  During the third quarter ended September 30, 2016, we incurred Adjusted EBITDA losses for start-up hospitals of approximately $9.0 million. A reconciliation of net income to Adjusted EBITDA is presented in table VIII of this release. Income per common share for the third quarter ended September 30, 2016 was $0.05 on a fully diluted basis, compared to income per common share of $0.22 for the same period, prior year. Excluding the non-operating loss, loss of early retirement of debt, and related tax effects, adjusted income per common share was $0.06 per diluted share for the third quarter ended September 30, 2016. Excluding the non-operating gain and related tax effect, adjusted income per common share was $0.08 per diluted share for the third quarter ended September 30, 2015. A reconciliation of income per common share to adjusted income per common share for both the third quarters ended September 30, 2016 and 2015 is presented in table IX of this release.

United Therapeutics Corporation (NASDAQ:UTHR), gained 7.16% and closed at $129.98 in the last trading session. The last trading range of the stock ranges between $124.44 and $130.33. During the 52-week trading session the minimum price at which share price traded, registered at $97.52 and reached to max level of $164.04. United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s principal therapeutic products and product candidates include Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH); Tyvaso, an inhaled prostacyclin therapy for PAH; Adcirca, a once-daily oral therapy for PAH; Orenitram, a prostacyclin analog for PAH; Unituxin, an antibody that binds to cancerous tumors and destroys the cancer cells; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *